Tratamiento de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el virus de la inmunodeficiencia humana en la era del tratamiento antirretrovírico de gran actividad

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 19, Issue 8, 2001, Pages 376-392

  Podzamczer, Daniel ^a   Arribas, José Ramón ^b   Mallolas, José ^c   Peña, José María ^b   Pulido, Federico ^d   Aguirrebengoa, Koldo ^e   Barros, Carlos ^f   Blazquez, Rosa ^g   Costa, José Ramón ^d   Dronda, Fernando ^h   Ena, Javier ⁱ   Gutiérrez, Félix ⁱ   Juega, Javier ^j   Labarga, Pablo ^k   Locutura, Jaime ^l   Aldeguer, José López ^m   Moreno, Santiago ^h,n   Noguerado, Arturo ^o   Ocaña, Imma ^p   Padilla, Belén ^q   Pérez Cecilia, Elisa ^r   Elías, M Jes's Pérez ^h   Portilla, Joaquín ^s   Rivero, Antonio ^t   Roca, Victor ^r   more..

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL DE CRUCES   (Spain)

^f HOSPITAL DE MÓSTOLES   (Spain)

^g HOSPITAL MORALES MESEGUER   (Spain)

^h HOSPITAL RAMÓN Y CAJAL   (Spain)

ⁱ HOSPITAL MARINA BAIXA   (Spain)

^j HOSPITAL JUAN CANALEJO   (Spain)

^k HOSPITAL SAN PEDRO   (Spain)

^l HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^m HOSPITAL UNIVERSITARIO LA FE   (Spain)

ⁿ Plan Nacional Sobre el Sida   (Spain)

^o Hospital Canto Blanco   (Spain)

^p HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^q HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^r HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^s HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^t HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; AMPRENAVIR; ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; CIDOFOVIR; CLOTRIMAZOLE; EFAVIRENZ; FAMCICLOVIR; FENTICONAZOLE; FLUCONAZOLE; FLUCYTOSINE; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LOPINAVIR; NEVIRAPINE; NYSTATIN; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; SERTACONAZOLE; UNINDEXED DRUG; VALACICLOVIR;

ANTIBIOTIC THERAPY; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CLINICAL FEATURE; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LEISHMANIA DONOVANI; LEUKOENCEPHALOPATHY; MYCOBACTERIUM AVIUM; OPPORTUNISTIC INFECTION; PARASITOSIS; PNEUMOCYSTIS CARINII; TOXOPLASMA GONDII; TUBERCULOSIS;

EID: 0035213657     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0213-005X(01)72670-5     Document Type: Article

References (133)

1. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency
2. Recent advances in the management of AIDS-related opportunistic infections
3. The management of opportunistic infections in the era of highly active antiretroviral therapy
4. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
5. Prevención de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el virus de la inmunodeficiencia humana en la era del tratamiento antirretrovírico de gran actividad
6. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients
7. HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: A 2-year study
8. Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis
9. Oropharyngeal candidiasis in patients with AIDS: Randomized comparison of fluconazole versus nystatin oral suspensions
10. Therapy for oropharyngeal candidiasis in HIV-infected patients: A randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches
11. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients
12. A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS
13. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS
14. Oropharyngeal candidiasis in patients with HIV: Suggested guidelines for therapy
15. Refractory mucosal candidiasis in patients with human immunodeficiency virus infection
16. Highly resistant esophageal candidiasis in patients with AIDS
17. Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection
18. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: Correlation of clinical response with in vitro susceptibility
19. A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: Clinical outcomes and development of fluconazole resistance
20. A prospective, randomized, double-blind trial of fluconazole vs. ketoconazole for candida esophagitis in AIDS
21. Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: A double-blind, randomized, controlled clinical study
22. Fluconazole vs. flucytosine in the treatment of esophageal candidiasis in AIDS patients: A double-blind, placebo-controlled study
23. Fluconazole vs itraconazole-flucytosine association in the treatment of esophageal candidiasis in AIDS patients. A double-blind, multicenter placebo-controlled study
24. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis
25. Clinical and mycological evaluation of fluconazole in the secondary prophylaxis of esophageal candidiasis in AIDS patients. An open, multicenter study
26. A comparison of fluconazole and ketoconazole in the oral treatment of vaginal candidiasis; report of a double-blind multicentre trial
27. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome
28. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis
29. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis
30. Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: Reliability of relatively high doses administered over a relatively short period
31. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial
32. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis
33. Use of high-fose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS
34. High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection
35. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS
36. A phase II dose escalation trial of high dose fluconazole with and without flucytosine for AIDS associated cryptococcal meningitis
37. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis
38. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis
39. Practice guidelines for the management of cryptococcal disease. Infectious disease society of America
40. Acyclovir: A decade later
41. Antiviral drugs
42. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial
43. Foscarnet-resistant herpes simplex virus infection in patients with AIDS
44. Management of acyclovir-resistant herpes simplex and varicellazoster virus infections
45. Current pharmacological approaches to the therapy of varicella zoster virus infections; a guide to treatment
46. Famciclovir and penciclovir: The mode of action of Famciclovir including its conversion to penciclovir
47. Famciclovir: A review of its pharmacological properties and therapeutic efficacy in herpes virus infection
48. Famciclovir: Review of clinical efficacy and safety
49. Foscarnet: A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis
50. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant
51. Treatment of Cytomegalovirus (CMV) in the era of highly active antiretroviral therapy
52. Cytomegalovirus disease in AIDS
53. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS
54. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: Oral ganciclovir and CMV polymerase chain reaction testing
55. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients
56. Treatment of AIDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy
57. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy
58. Progressive multifocal leukoencephalopathy, HIV, and highly active antiretroviral therapy
59. Progressive multifocal leucoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy
60. Treatment of progressive multifocal leukoencephalopathy (PML) with cidofovir in an AIDS patients
61. Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy
62. Prevention and treatment of tuberculosis among patients infected with HIV: Principles of therapy and revised recommendations
63. Incidencia de la tuberculosis en España: Resultados del Proyecto Multicéntrico de Investigación en Tuberculosis (PMIT)
64. Estudio transversal multihospitalario de tuberculosis y resistencias en Madrid (Octubre 1993-Abril 1994)
65. Principles of therapy of tuberculosis in the modern era
66. Diagnóstico y tratamiento de las infecciones por micobacterias en pacientes con VIH/sida
67. Fiebre de origen desconocido e infección por VIH
68. Resistencias primarias de Mycobacterium tuberculosis en diez hospitales de la comunidad de castilla y león
69. Documento de consenso sobre tratamientos directamente observados en tuberculosis
70. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficieney virus: Differences in study outcomes
71. Therapeutic implications of drug interactions in the treatment of HIV-related tuberculosis
72. The treatment of tuberculosis in HIV-infected patients
73. Use of rifabutin with protease inhibitors for HIV-infected patients with tuberculosis
74. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors on nonnucleoside reverse transcriptase inhibitors
75. Pharmacokinetic interactions between rifampin and efavirenz in patients with tuberculosis and HIV infection
76. Treatment of tuberculosis in HIV-infected patients: Safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin
77. Infección por Mycobacterium avium complex
78. ACTG 223: An open prospective, randomized, study comparing efficacy and safety of claritromycin plus ethambutol, rifabutin or both for treatment of MAC disease in patients with AIDS
79. A randomized, placebo-controlled study of rifabutin added to a regimen of claritromycin and ethambutol for treatment of disseminated infection with MAC
80. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteriemia in AIDS: Rifabutin, ethambutol and claritromicine versus rifampin, ethambutol, clofazimine and ciprofloxacin
81. Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: Results of a large prospective randomized treatment trial
82. Expert panel for corticosteroids as adjunctive therapy for Pneumocystis pneumonia. Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis pneumonia in the acquired immunodeficiency syndrome
83. Steroids do not enhance the risk of developing tuberculosis or other AIDS-related disease in HIV-infected patients treated for Pneumocystis carinii pneumonia
84. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: A prospective randomized trial
85. Pentamidine aerosol versus trimethoprim-sulfamethoxazole for Pneumocystis carinii in acquired immunodeficiency syndrome
86. A five-year retrospective review of adverse drug reactions and their risk factor in human immunodeficiency virus-infected patients who were receiving in pentamidine therapy for PCP
87. Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infect with human immunodeficiency virus
88. Comparison of three regimens for treatment of mild to moderate PCP in patients with AIDS
89. Inhaled or intravenous pentamidine therapy for Pneumocystis carinii pneumonia in AIDS
90. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS
91. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS
92. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone
93. Clindamycin and primaquine therapy for mild-to-moderate episodes of Pneumocystis carinii pneumonia in patients with AIDS: AIDS Clinical Trials Group 044
94. Toxoplasmosis cerebral
95. Treatment of toxoplasmic encephalitis (TE) in patients with AIDS: A randomized trial comparing pryrimethamine plus clindamycin (PC) to pyrimethamine plus sulfonamides (PS)
96. Pyrimethamine-clindamycin versus pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS
97. Synergistic activity of azithormycin and pyrimethamine or sulfadiazine in acute experimental toxoplasinosis
98. Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis
99. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS
100. Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS
101. Cotrimoxazole therapy of Toxoplasma gondii encephalitis in AIDS patients
102. Treatment and prophylaxis of Isospora belli infection in patients with the acquired immunodeficiency syndrome
103. Treatment of isosporiasis with combined albendazole and ornidazole in patients with AIDS
104. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial
105. Disseminated microsporidosis due to Septata intestinalis in nine patients infected with the human immunodeficiency virus: Response to therapy with albendazole
106. Thalidomide a novel therapy for microsporidosis
107. Paromomycin for cryptosporidiosis in AIDS: A prospective, double-blind trial
108. Combination drug therapy for cryptosporidiosis in AIDS
109. Paramomycin: No more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection
110. Efficacy of octreotide in the management of chronic diarrhoea in AIDS
111. Treatment of HIV-1 associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy
112. Cyclospora infection in adults infected with HIV. Clinical manifestations, treatment and prophylaxis
113. Leishmania and human immunodeficiency virus coinfection: The first 10 years
114. Treatment of visceral leishmaniasis in HIV-infected patients: A randomized trial comparing meglumine antimoniate with amphotericin B
115. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)
116. Tratamiento de la coinfección VIH-leishmaniasis visceral con un nuevo régimen de anfotericina B liposomal (AMB-L)
117. Restoration of the immune system with anti-retroviral therapy
118. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy
119. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy
120. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy
121. High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors
122. Focal mycobacterial limphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease
123. Mycobacterial lymphadenitis associated with the initiation of combination
124. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS
125. Pulmonary tuberculosis in AIDS patients: Transient chest radiographic worsening after initiation of antiretroviral therapy
126. Paradoxical worsening of AIDS-associated progressive multifocal leukoencephalopathy following HAART
127. Hepatitis C virus associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease?
128. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral therapy
129. Mucosal Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected patient
130. Cytomegalovirus (re)activation plays no role in the ocular vitritis observed after initiation of highly active antiretroviral therapy